Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

GNP Consultants LLC

Neither a doctor nor a teaching hospital

Research payments

$416,040

75 payments

Through program year 2025, GNP Consultants LLC is reported as receiving $416,040 in research payments, across 75 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $167,292 37
2024 Research $145,608 22
2023 Research $60,972 9
2022 Research $6,375 4
2021 Research $28,293 2
2020 Research $7,500 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. GlaxoSmithKline, LLC. $136,905 36 payments
  2. AbbVie, Inc. $80,666 9 payments
  3. Janssen Research & Development, LLC $63,530 15 payments
  4. Eli Lilly and Company $61,820 6 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $29,731 4 payments
  6. Otsuka Pharmaceutical Development & Commercialization, Inc. $25,588 1 payment
  7. Sun Pharmaceutical Industries Inc. $13,300 3 payments
  8. Alexion Pharmaceuticals, Inc. $4,500 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Multicentre Randomized, Double-Blind, Placebo-Controlled, Dose-Findi $136,905 36 payments
  2. A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus $63,530 15 payments
  3. Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) $40,276 3 payments
  4. Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) $31,364 4 payments
  5. A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) $29,731 4 payments
  6. A Randomized, Controlled Pragmatic Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $28,812 4 payments
  7. Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Active Primary Sjgrens Syndrome (PSS) $25,588 1 payment
  8. Taltz Psa Observational Study $21,804 1 payment
  9. Efficacy and Safety of ILUMYA Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $12,000 1 payment
  10. A Phase 4 Randomized Double-Blind Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine $11,204 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record